Instrument NameGinkgo Bioworks Hldgs IncInstrument Symbol(DNA-N)

Instrument ExchangeNYSE

The company is forging ahead with next-generation drug development solutions.

Could this beaten-down stock turn things around in the near future?

The risks may resolve in a year or so but seizing the opportunities will take longer.

The company is using artificial intelligence, and planning to help others use AI empowered by its data collection.

Its ambitious business model may not be sustainable.

Have shares of the troubled life sciences business fallen too far?

Efficiency in core processes is set to increase substantially due to AI.

A recovery plan is underway, but it isn't a slam dunk.

There was double trouble for this beaten-down biotech stock.

These pharma and biotech players could become long-term winners.

This innovative biotechnology company hopes to turn things around.

Its vision is ambitious, but can it actually be made to work?

You don't need to buy her picks, but it's worth understanding them.

It needs to work within the constraints imposed by these three issues.

The number of cell engineering partnerships Ginkgo Bioworks has is way up, but the same can't be said about its stock price.

Ginkgo Bioworks has become a penny stock -- and that's the least of its problems,

Can this struggling stock turn things around?

These four small-cap stocks scan as deeply undervalued right now.

A few enterprising businesses are marketing themselves differently.

A whole ecosystem of supporting companies offers additional upside

This company has a long way to go before investors will see rewards.

The collaboration could help solve challenges for both businesses.

These stocks, a bargain today, are players to hold on to for the long term.

They might not be profitable yet, but they're swinging for the fences.

These stocks could rocket higher, but they also present significant risks.